<DOC>
	<DOCNO>NCT00691522</DOCNO>
	<brief_summary>This phase II , multicenter , open-label , image study hCRF reduction PBE patient primary malignant metastatic brain tumor . Approximately 30 60 patient assign 1 3 treatment group receive study drug 28 day</brief_summary>
	<brief_title>Imaging Study XERECEPT® Treatment Peritumoral Brain Edema ( PBE )</brief_title>
	<detailed_description>The purpose study investigate effect 3 different regimen subcutaneous ( SC ) administer hCRF ( 1.0 mg every [ Q ] 8 hour [ h ] , 1.5 mg Q12h , 1.0 mg Q12h ) reduction PBE patient primary malignant metastatic brain tumor define MRI index .</detailed_description>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Brain Edema</mesh_term>
	<mesh_term>Corticotropin-Releasing Hormone</mesh_term>
	<criteria>18 year age old . Written inform consent provide document . Primary malignant metastatic brain tumor either asymptomatic symptomatic patient life expectancy estimation 3 month A pretreatment MRI brain scan must identify least 1 dominant tumor lesion relate PBE radiologically ( visibly ) distinct main tumor mass ; combine tumoredema lesion must &gt; 2 cm long diameter ( least 1 slice ) visible 3 consecutive , 4 mm section MRI . No dexamethasone antiangiogenic treatment least 14 day prior Baseline throughout study . A Karnofsky Performance Score &gt; 60 Screening ( Visit 1 ) Baseline A negative serum pregnancy test Screening ( Visit 1 ) require woman childbearing potential . • Lowgrade glioma , recurrent glioma , suspect lymphoma , know human immunosuppressive virus ( HIV ) infection . Patients require surgery , radiosurgery radiation surgery therapy Patients experience severe symptom related PBE Patients MRI contraindicate reason . Signs and/or symptom relatively severe cerebral herniation . Concurrent enrollment investigational drug device study , plan enroll study 3 4 week study treatment . Systemic corticosteroid use ( exception inhaler asthma ) . Use dexamethasone ( eg , antiemetic ) screen study Use antiangiogenic/antivascular endothelial growth factor ( VEGF ) therapy anticonvulsant therapy ( patient 's liver function test ( LFTs ) &gt; 3 time upper limit normal ) 14 day prior randomization Serious concomitant cardiovascular , pulmonary , renal , gastrointestinal , endocrine metabolic disease , opinion Investigator Medical Monitor , would put patient unusual risk study participation . Known renal insufficiency screen glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73 m2 . Central nervous system infection , human immunosuppressive virus ( HIV ) positive ongoing infectious process . For female patient : pregnancy , breastfeed refusal practice birth control childbearing potential study . Inability patient follow treatment regimen . Known history methionine allergy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>PERITUMORAL BRAIN EDEMA</keyword>
	<keyword>PRIMARY MALIGNANT BRAIN TUMORS</keyword>
	<keyword>METASTATIC BRAIN TUMORS</keyword>
</DOC>